EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge

Qunlong Li, Hongzhuan He, Yuxi Zhou, Jihong Wang, Huan Chen, Hui Liu

The Journal of Infection in Developing Countries · 2024

DOI: 10.3855/jidc.19193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Qunlong Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu Kanghua Biological Products Co., Ltd. Chengdu 610100, Sichuan, China. Hauptthemen laut MEDLINE: Rabies Vaccines, Rabies, Vaccines, Synthetic, Genetic Vectors. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Rabies is a fatal infectious disease, that poses a major public health threat in developing countries. With an annual death toll of approximately 59,000, more than half of which are children, an urgent need exists for a safe, affordable, and effective preventive measure against rabies virus infection. Methodology: A recombinant rabies vaccine called Ad5-dRVG was constructed by introducing two copies of the rabies virus glycoprotein into a human adenoviral vector. Virus-neutralizing assays and virus challenge experiments were employed to evaluate the Ad5-dRVG vaccine.

Results

Our findings demonstrate that a single dose of Ad5-dRVG, administered either intramuscularly or orally, elicited significantly stronger immune responses than Ad5-RVG. Moreover, both vaccines provided complete protection in mice. Notably, the vaccine exhibited remarkable efficacy even at low doses, suggesting potential cost reduction in production.

Conclusions

The development of the Ad5-dRVG recombinant rabies vaccine represents a significant advancement in rabies prevention. Its enhanced immunogenicity, demonstrated efficacy and potential cost savings make it a promising candidate for widespread use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rabies VaccinesRabiesVaccines, SyntheticGenetic VectorsGlycoproteinsRabies virusAnimalsMiceFemaleAntibodies, ViralAdenoviridaeMice, Inbred BALB CInjections, IntramuscularAntibodies, NeutralizingHumansDisease Models, AnimalAdministration, OralViral Envelope ProteinsVaccine Efficacy

Stichwörter der Autor:innen

Rabiesadenovirusglycoproteinrecombinant rabies vaccine

Substanzen

Rabies VaccinesVaccines, SyntheticGlycoproteinsAntibodies, ViralAntibodies, NeutralizingViral Envelope Proteins

Autor:innen und Institutionen

  • Chengdu Kanghua Biological Products Co., Ltd. Chengdu 610100, Sichuan, China.

Zitieren

APA

Li, Q., He, H., Zhou, Y., Wang, J., Chen, H., & Liu, H. (2024). A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.19193

Vancouver

Li Q, He H, Zhou Y, Wang J, Chen H, Liu H. A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.19193

BibTeX
@article{Li2024,
  author = {Li, Qunlong and He, Hongzhuan and Zhou, Yuxi and Wang, Jihong and Chen, Huan and Liu, Hui},
  title = {A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge},
  journal = {The Journal of Infection in Developing Countries},
  year = {2024},
  doi = {10.3855/jidc.19193}
}
Kostenlos starten →